06/04/2026
🧬 Biotech startups don’t just face scientific challenges.
They face financial endurance challenges too.
One of the biggest reasons biotech companies burn through cash faster than expected?
Poor forecasting.
Long R&D cycles, regulatory timelines, and operational costs require financial planning that looks far beyond the next quarter.
Without visibility into runway, spending, and long-term strategy, even promising companies can struggle to scale sustainably.
At Growise CPAs, we help biotech founders build financial systems designed for long-term growth and smarter decision-making.